Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient

Yves-Marie Pers; Marie Godfrin-Valnet; Joseph Lambert; Clémentine Fortunet; Elodie Constant; Thibault Mura; Béatrice Pallot-Prades; Christian Jorgensen; Jean-Francis Maillefert; Hubert Marotte; Daniel Wendling; Philippe Gaudin

doi:10.3899/jrheum.140673

Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient

J Rheumatol. 2015 Apr;42(4):580-4. doi: 10.3899/jrheum.140673. Epub 2015 Feb 1.

Affiliations

¹ From the Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital; INSERM CIC 1001, Arnaud de Villeneuve University Hospital, Montpellier; Rheumatology, Besançon University Teaching Hospital, Besançon; Rheumatology Unit, Grenoble University Hospital, Grenoble; Rheumatology, Dijon University Hospital, Dijon; Rheumatology Unit, Saint-Étienne University Hospital, Saint-Étienne, France.Y-M. Pers, MD; C. Jorgensen, MD, PhD, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital; M. Godfrin-Valnet, MD; D. Wendling, MD, PhD, Rheumatology, Besançon University Teaching Hospital; J. Lambert, MD; P. Gaudin, MD, PhD, Rheumatology Unit, Grenoble University Hospital; C. Fortunet, MD; J-F. Maillefert, MD, PhD, Rheumatology, Dijon University Hospital; E. Constant, MD; B. Pallot-Prades, MD; H. Marotte, MD, PhD, Rheumatology Unit, Saint-Etienne University Hospital; T. Mura, MD, PhD, INSERM CIC 1001, Arnaud de Villeneuve University Hospital. ympers2000@yahoo.fr.
² From the Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital; INSERM CIC 1001, Arnaud de Villeneuve University Hospital, Montpellier; Rheumatology, Besançon University Teaching Hospital, Besançon; Rheumatology Unit, Grenoble University Hospital, Grenoble; Rheumatology, Dijon University Hospital, Dijon; Rheumatology Unit, Saint-Étienne University Hospital, Saint-Étienne, France.Y-M. Pers, MD; C. Jorgensen, MD, PhD, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital; M. Godfrin-Valnet, MD; D. Wendling, MD, PhD, Rheumatology, Besançon University Teaching Hospital; J. Lambert, MD; P. Gaudin, MD, PhD, Rheumatology Unit, Grenoble University Hospital; C. Fortunet, MD; J-F. Maillefert, MD, PhD, Rheumatology, Dijon University Hospital; E. Constant, MD; B. Pallot-Prades, MD; H. Marotte, MD, PhD, Rheumatology Unit, Saint-Etienne University Hospital; T. Mura, MD, PhD, INSERM CIC 1001, Arnaud de Villeneuve University Hospital.

PMID: 25641885
DOI: 10.3899/jrheum.140673

Abstract

Objective: To assess the relationship between the body mass index (BMI) and the efficacy of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA).

Methods: We conducted a retrospective study in 222 patients with RA followed by 5 centers. The European League Against Rheumatism response was evaluated at 6 months. Univariate and multivariate logistic regressions were performed.

Results: No significant association between the BMI and the response to TCZ at 6 months was found after adjustment for potential confounding factors (adjusted OR 0.45, 95% CI 0.16-1.24, p = 0.13 and OR 1.19, 95% CI 0.31-4.48, p = 0.78 for BMI 25-30 kg/m(2) and BMI > 30 kg/m(2), respectively, compared to BMI < 25 kg/m(2)).

Conclusion: Response to TCZ in patients with RA is not influenced by the baseline BMI, in contrast to anti-tumor necrosis factor drugs.

Keywords: BODY MASS INDEX; RESPONSE; RHEUMATOID ARTHRITIS; TOCILIZUMAB.

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / physiopathology
Body Mass Index*
Female
Humans
Male
Middle Aged
Retrospective Studies
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antirheumatic Agents
tocilizumab